BRIEF—Century Therapeutics founded with $250 million

A new company, Century Therapeutics, has been launched to develop allogeneic or off-the-shelf immune cell therapies for cancer, using technology built on induced pluripotent stem cells (iPSCs).

The company was founded with $250 million from Versant Ventures, Bayer and Fujifilm Cellular Dynamics.

Chief executive Lalo Flores said: "The financial support and expertise from this consortium of partners will enable Century to realize the full potential of our iPSC platform and expand patient access to cell therapy.”